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The relationship between tumour stage, grade, elevated C-reactive protein concentration (o10/410mgl
 1), adjuvant therapy and
survival was examined in patients with biopsy proven bladder cancer (n¼105). On multivariate analysis stage (HR 3.37, 95% CI
1.37–8.29, P¼0.008), grade (HR 2.01, 95% CI 1.14–3.57, P¼0.017) and preoperative C-reactive protein (HR 3.31, 95% CI 1.09–
10.09, P¼0.035) were independently associated with cancer-specific survival.
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Bladder cancer is the fourth most common malignancy in United
Kingdom in men and the eighth in women with a total of 12500
new cases each year causing 5000 deaths annually (CRC
CancerStats, 2002). More than 90% of bladder cancers diagnosed
in the Western world, are transitional cell carcinomas and
constitute a significant proportion of the general urological
consultants’ workload due to its high prevalence and recurrent
nature.
It is increasingly recognised that, in addition to tumour stage,
disease progression is dependent on a complex interaction of the
tumour and host inflammatory response (Balkwill and Mantovani,
2001; Coussens and Werb, 2002). Indeed, the systemic inflamma-
tory response, as evidenced by elevated circulating concentrations
of C-reactive protein, has been shown to be a stage independent
prognostic factor in a variety of operable tumours (Mahmoud and
Rivera, 2002; Ikeda et al, 2003; McMillan et al, 2003). To our
knowledge there has been only one previous study that has
examined the prognostic value of C-reactive protein in patients
with invasive bladder cancer (O’Quigley et al, 1981).
The aim of the present study was to examine the relationship
between stage, grade, C-reactive protein and cancer-specific
survival in patients with superficial or invasive bladder cancer.
PATIENTS AND METHODS
Patients with biopsy proven transitional cell carcinoma presenting
to a single urological unit at Glasgow Royal Infirmary between
1992 and 1999 were reviewed. Those patients with a measurement
of C-reactive protein prior to or 3–6 months following transur-
ethral resection of bladder tumour were included in the study as
previously described (McMillan et al, 2003). Tumour stage was
assessed using the UICC guidelines, and tumour grade performed
according to the WHO grading system. Date and cause of death
were obtained from the Cancer Registry, Scotland using ICD 9
code (bladder cancer 1889).
Routine laboratory measurement of patient’s serum for C-
reactive protein concentration was performed. The limit of
detection of the assay was a C-reactive protein concentration
lower than 5mgl
 1. The coefficient of variation, over the range of
measurement, was less than 5% as established by routine quality
control procedures. C-reactive protein measurement of greater
than 10mgl
 1 was considered to indicate the presence of systemic
inflammatory response. (O’Gorman et al, 2000).
The Research Ethics Committee of North Glasgow NHS Trust
approved the study.
STATISTICAL ANALYSIS
Survival analysis was performed using the Cox proportional
hazard model with patient age, sex, tumour stage and grade and C-
reactive protein concentration as prognostic variables. Deaths up
to September 2004 were included in the analysis.
Multivariate survival analysis was performed using stepwise
backward procedure to derive a final model of the variables that
had a significant independent relationship with survival. To
remove a variable from the model, the corresponding P-value
had to be a greater than 0.10. Analysis was performed using SPSS
software (SPSS, Chicago, IL, USA).
RESULTS
The characteristics of patients with bladder cancer (n¼105) are
shown in Table 1. The majority were male, over the age of 65 years,
had superficial disease (Ta, T1) and had elevated C-reactive
protein concentrations either pre- or postoperatively. In total, 24
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spatients had adjuvant therapy (eight radiotherapy, eight BCG,
eight cystectomy).
In all, 32 patients had C-reactive protein concentrations
determined both prior to and following the resection. Of the 20
patients with an elevated preoperative value, 12 (60%) had a raised
concentration after the operation. Of the 12 patients with a normal
preoperative value, nine (75%) had a postoperative value in the
normal range.
During the follow-up period 80 patients died, 41 of them from
bladder cancer and the mean cancer-specific survival was 82.9
months (95% confidence interval 70.8–94.9). On univariate
analysis, stage (Po0.001), grade (Po0.01) and elevated C-reactive
protein preoperatively (Po0.05) and postoperatively (Po0.01)
were significantly associated with overall survival. Also, stage
(Po0.001), grade (Po0.001) and elevated C-reactive protein
preoperatively (Po0.05) and postoperatively (Po0.01) were
significantly associated with cancer-specific survival (Table 2).
On multivariate analysis of patients who had a preoperative C-
reactive protein determination, stage (HR 4.00, 95% CI 2.02–7.94,
Po0.001) and preoperative C-reactive protein (HR 2.73, 95% CI
1.23–6.07, P¼0.014) were independently associated with overall
survival. Also, stage (HR 3.37, 95% CI 1.37–8.29, P¼0.008), grade
(HR 2.01, 95% CI 1.14–3.57, P¼0.017) and preoperative C-
reactive protein (HR 3.31, 95% CI 1.09–10.09, P¼0.035) were
independently associated with cancer-specific survival. Those
patients with an elevated preoperative C-reactive protein concen-
tration (410mgl
 1) had a mean cancer-specific survival of 65.5
months (95% CI 46.8–84.2) compared with 103.7 months (95% CI
81.8–125.6) in those patients with a C-reactive protein concentra-
tion in the normal range (p10mgl
 1).
DISCUSSION
In the present study, both tumour grade and the presence of a
systemic inflammatory response, as evidenced by elevated
circulating concentrations of C-reactive protein, were independent
predictors of cancer-specific survival in patients with bladder
cancer. These results confirm the importance of tumour grade as a
stage independent prognostic factor (Ali-El-Dein et al, 2003;
Nishiyama et al, 2004) and are consistent with the work of
O’Quigley et al (1981), who reported that an elevated C-reactive
protein concentration, measured by radial immunodiffusion and
using the limit of sensitivity of 12mgl
 1 as a cutoff, was associated
with poor survival in patients with invasive bladder cancer.
Furthermore, because C-reactive protein concentration is
independent of tumour stage and grade, the presence or absence
of a systemic inflammatory response, might, form the basis of a
new prognostic score that reflects not only the tumour but also the
host response. Indeed, this approach has recently been used in
both lung and colorectal cancer (Forrest et al, 2003; Canna et al,
2004).
Although in the present study, it may appear from the present
results that an elevated postoperative C-reactive protein concen-
tration is a better predictor of cancer-specific survival than an
elevated concentration prior to resection, in a clinical context the
measurement of preoperative CRP concentration is likely to be of
more value because it would allow planning of adjuvant therapy.
The mechanisms by which a systemic inflammatory response
might impact on cancer-specific survival are not clear. However, it
is known that as part of the systemic inflammatory response to the
tumour there is a release of proinflammatory cytokines and growth
factors, which not only stimulate tumour growth (Abramovitch
et al, 1999; Coussens and Werb, 2002) but also produce profound
catabolic effects on host metabolism (Kotler, 2000). For example,
interleukin-6, produced by the tumour or infiltrating inflammatory
cells, is recognised as a growth promoter in bladder cancer
(Okamoto et al, 1997; Andrews et al, 2002). Interleukin-6 also
stimulates liver production of acute-phase proteins, such as C-
reactive protein, which increases the demand for certain amino
Table 1 Clinical characteristics and survival in patients with bladder
cancer
Patients
105 (100%)
Age
p65years 37 (35)
465years 68 (65)
Sex
Male 75 (71)
Female 30 (29)
Stage
Superficial (Ta,T1) 76 (72)
Invasive 29 (28)
Grade
G1 36 (34)
G2 31 (30)
G3 38 (36)
Preoperative C-reactive protein
p10mgl
 1 16 (15)
410mgl
 1 43 (41)
Postoperative C-reactive protein
p10mgl
 1 36 (34)
410mgl
 1 42 (40)
Adjuvant therapy
No 81 (77)
Yes 24 (23)
Alive 25 (24)
Dead
Bladder cancer specific 41 (39)
Intercurrent 39 (37)
Table 2 The relationship between variables and overall and cancer-specific survival in patients with bladder cancer: univariate analysis
Overall Cancer specific
Hazard ratio P-value
a Hazard ratio P-value
a
Age (p65/465years) 0.063 0.142
Sex (male/female) 0.338 0.803
Stage
(Superficial/invasive) 2.82 (1.74–4.57) o0.001 4.96 (2.61–9.41) o0.001
Grade (G1/G2/G3) 1.48 (1.14–1.92) 0.004 2.17 (1.45–3.23) o0.001
Preoperative C-reactive protein (p10/410mgl
 1) 2.50 (1.15–5.43) 0.021 3.03 (1.04–8.87) 0.043
Postoperative C-reactive protein (p10/410mgl
 1) 2.31 (1.34–3.97) 0.003 3.28 (1.41–7.63) 0.006
Adjuvant therapy (No/Yes) 0.537 0.732
Values in parentheses are 95% confidence intervals.
aCox proportional hazard model.
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sacids, which, if limited in the diet, must be obtained from the
breakdown of skeletal muscle (McMillan et al, 1998; Preston et al,
1998). In this way, the presence and magnitude of a chronic
systemic inflammatory response may produce a progressive
nutritional and functional decline, ultimately resulting in reduced
survival.
In summary, it would appear that the systemic inflammatory
response is a stage and grade independent prognostic factor in
patients with bladder cancer. The role of the systemic inflamma-
tory response in determining disease-specific survival in patients
with bladder cancer is worthy of further study to establish its value
as a prognostic factor.
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